Research progress of interleukin-23 inhibitors in treating psoriasis
MA Yan-qiao
CHEN Ji
LI Lei
TAN Dan-feng
TAO Yue-ying
CHEN Ze-hui
TIAN Ying-biao
Abstract：Psoriasis is a common chronic inflammatory dermatosis, which seriously threatens the physical and mental health of human beings and is widely concerned by scholars at home and abroad. However, the exact pathogenesis and etiology of psoriasis is not clear. In recent years, various biological agents that inhibit the corresponding target of immune response have achieved remarkable curative effect in the treatment of moderate to severe psoriasis. A large number of experimental and clinical studies have confirmed that interleukin-23 (IL-23)plays an important role in the pathogenesis of psoriasis. At present, great progress has been made in the development of new drugs for the treatment of psoriasis against the IL-23 target. This article reviews the progress of IL-23 inhibitors in the treatment of psoriasis.
Keywords：psoriasispathogenesisinterleukin-23 inhibitortildrakizumabguselkumabrisankizumab
Publication Date：2018-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：6( 899-904 )